Results 41 to 50 of about 7,656 (201)

Ribosome-Inactivating Proteins from Plants: A Historical Overview

Molecules, 2016
This review provides a historical overview of the research on plant ribosome-inactivating proteins (RIPs), starting from the first studies at the end of eighteenth century involving the purification of abrin and ricin, as well as the immunological ...
Andrea Bolognesi, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Letizia Polito   +4 more
doaj   +1 more source

Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes

Toxins, 2023
The production of therapeutic recombinant toxins requires careful host cell selection. Bacteria, yeast, and mammalian cells are common choices, but no universal solution exists.
Luana di Leandro, Martina Colasante, Giuseppina Pitari, Rodolfo Ippoliti   +3 more
doaj   +1 more source

Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers

Toxins, 2016
The toxic moiety of almost all protein-based targeted toxins must enter the cytosol of the target cell to mediate its fatal effect. Although more than 500 targeted toxins have been investigated in the past decades, no antibody-targeted protein toxin has ...
Hendrik Fuchs, Alexander Weng, Roger Gilabert-Oriol   +2 more
doaj   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Technology and Biological Weapons: Future Threats [PDF]

, 2004
Ye
Davison, N., Millett, P., Nixdorff, K.
core  

Dianthin and Its Potential in Targeted Tumor Therapies [PDF]

, 2019
Dianthin enzymes belong to ribosome-inactivating proteins (RIPs) of type 1, i.e., they only consist of a catalytic domain and do not have a cell binding moiety.
Fuchs, Hendrik
core   +1 more source

Mechanistic Insights Into Photocatalytic Materials for Toxic Pollutants: Environmental Remediation of Personal Care Products

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Photocatalytic materials have emerged as promising solutions for environmental applications due to their ability to degrade organic pollutants under sunlight or artificial light. In this review, recent progress on the photocatalytic materials used for the degradation of pharmaceutical personal care products (PPCPs) in environmental ...
Urvashi Sen, Gunjan Chauhan, Surbhi Soni, Monika Vats, Anand Kumar, Indra Bahadur   +5 more
wiley   +1 more source

An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells

Antibodies, 2013
Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use ...
Daniel A. Vallera, Nate N. Waldron
doaj   +1 more source

Cellular Respiration in Thymic Fragments from Mice

Frontiers in Bioscience-Landmark, 2022
Background: This report aims to detail the use of the phosphorescence oxygen analyzer for in vitro investigation of thymic responses to pharmaceutical agents, in particular immunosuppressants and immunomodulators.
Mariam Alshamsi, Maya Hassane, Farida Almarzooqi, Abdul-Kader Souid   +3 more
doaj   +1 more source

Immunotoxins for leukemia

Blood, 2014
AbstractUnconjugated monoclonal antibodies that target hematopoietic differentiation antigens have been developed to treat hematologic malignancies. Although some of these have activity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies have limited efficacy as single agents in the treatment of leukemia.
Alan S, Wayne, David J, Fitzgerald, Robert J, Kreitman, Ira, Pastan   +3 more
openaire   +3 more sources